When did GoodRx Holdings, Inc. report Q4 2024 earnings?

GoodRx Holdings, Inc. (GDRX) reported Q4 2024 earnings on February 27, 2025 before market open.

What were GoodRx Holdings, Inc.'s Q4 2024 revenue and EPS?

GoodRx Holdings, Inc. reported revenue of $198.6M and eps of $0.09 for Q4 2024.

Did GoodRx Holdings, Inc. beat estimates in Q4 2024?

Revenue missed the consensus estimate of $199.7M by $1.1M. EPS missed the consensus estimate of $0.10 by $0.01.

Where can I find GoodRx Holdings, Inc.'s Q4 2024 SEC filings?

You can read the 10-K periodic report (0001809519-25-000040) directly on SEC EDGAR. The filing index links above go to sec.gov.

GoodRx Holdings, Inc. GDRX Q4 2024 Annual earnings

Reported February 27, 2025 · Before market open

Revenue$198.6MMiss by $1.1M

EPS$0.09Miss by $0.01

Revenue estimate$199.7M

EPS estimate$0.10

Next report

Aug 5, 2026 (In 1 week)

Revenue estimate$193.2M

EPS estimate$0.08

Financials

Q4 2024

Income statement

See full

Revenue$198.6M+1.0%

Gross profit$186.4M+2.7%

Operating income$18.2M+199%

Net income$6.7M+126%

EPS (diluted)$0.02+133%

Balance sheet

See full

Cash & equivalents$448.3M-33.3%

Total debt$543.4M-23.6%

Total equity$724.7M-4.9%

Total assets$1.4B-12.6%

Cash flow

See full

Operating cash flow$44.7M+182%

CapEx$162.0K-60.4%

Free cash flow$44.6M+188%

Valuation & ratios

Valuation

as of 12/31/24

See full

Market cap$1.77B-34.4%

Enterprise value$1.87B-31.9%

P/E108.1×—

P/S2.2×-1.4×

Profitability

See full

Gross margin93.9%+2.8pp

Operating margin8.3%+6.4pp

Net margin2.1%+1.5pp

FCF margin23.1%+4.8pp

Returns & leverage

See full

Return on equity2.2%+1.6pp

Debt / equity0.7×-0.2×

Current ratio5.3×-1.8×

Segments

By product

See full

Prescription transactions revenue$145.0M+0.8%

Pharma Direct revenue$28.1M+15.1%

Subscription revenue$20.7M-10.7%

Other revenue$4.8M-7.6%

Versus estimates

Revenue

Q1 2026$194.0MBeat by $8.6M Q4 2025$194.8MBeat by $1.5M Q3 2025$196.0MBeat by $2.8M Q2 2025$203.1MMiss by $2.2M Q1 2025$203.0MBeat by $767.5K

Q4 2024$198.6MMiss by $1.1M

Diluted EPS

Q1 2026$0.07In line Q4 2025$0.09In line Q3 2025$0.08Miss by $0.01 Q2 2025$0.09Miss by $0.01 Q1 2025$0.09In line

Q4 2024$0.09Miss by $0.01

Ask the moment GoodRx Holdings, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did GoodRx Holdings, Inc. report Q4 2024 earnings?: GoodRx Holdings, Inc. (GDRX) reported Q4 2024 earnings on February 27, 2025 before market open.
What were GoodRx Holdings, Inc.'s Q4 2024 revenue and EPS?: GoodRx Holdings, Inc. reported revenue of $198.6M and eps of $0.09 for Q4 2024.
Did GoodRx Holdings, Inc. beat estimates in Q4 2024?: Revenue missed the consensus estimate of $199.7M by $1.1M. EPS missed the consensus estimate of $0.10 by $0.01.
Where can I find GoodRx Holdings, Inc.'s Q4 2024 SEC filings?: You can read the 10-K periodic report (0001809519-25-000040) directly on SEC EDGAR. The filing index links above go to sec.gov.